129401-88-3

Basic information

• Product Name: N-acryloyl-N'-phenylpiperazine
• Synonyms: N-acryloyl-N'-phenylpiperazine
• CAS NO: 129401-88-3
• Molecular Formula: C13H16 N2 O
• Molecular Weight: 216.2789
• Mol File: 129401-88-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 406.1°Cat760mmHg
• Flash Point: 188.8°C
• Appearance: /
• Density: 1.105g/cm³
• CAS DataBase Reference: N-acryloyl-N'-phenylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: N-acryloyl-N'-phenylpiperazine(129401-88-3)
• EPA Substance Registry System: N-acryloyl-N'-phenylpiperazine(129401-88-3)

Safety Data

• Hazardous Substances Data: 129401-88-3(Hazardous Substances Data)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 
• 15486-96-1 3-Bromopropionyl chloride 
• 814-68-6 acryloyl chloride 

Relevant articles and documents

Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives

One of the main challenges for nowadays medicine is drugs selectivity. In COX-1 and COX-2, the active sites are composed of the same group of amino acids with the exception of the only one residue in position 523, in COX-1 is an isoleucine, while in COX-2

COMPOSITIONS AND METHODS FOR MODULATING PPP2R1A

Disclosed herein, inter alia, are compositions and methods useful for modulating PPP2R1 A and for the treatment of cancer.

Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in reticulon 4 that impairs ER morphology and cancer pathogenicity

Chemical genetics has arisen as a powerful approach for identifying novel anti-cancer agents. However, a major bottleneck of this approach is identifying the targets of lead compounds that arise from screens. Here, we coupled the synthesis and screening of fragment-based cysteine-reactive covalent ligands with activity-based protein profiling (ABPP) chemoproteomic approaches to identify compounds that impair colorectal cancer pathogenicity and map the druggable hotspots targeted by these hits. Through this coupled approach, we discovered a cysteine-reactive acrylamide DKM 3-30 that significantly impaired colorectal cancer cell pathogenicity through targeting C1101 on reticulon 4 (RTN4). While little is known about the role of RTN4 in colorectal cancer, this protein has been established as a critical mediator of endoplasmic reticulum tubular network formation. We show here that covalent modification of C1101 on RTN4 by DKM 3-30 or genetic knockdown of RTN4 impairs endoplasmic reticulum and nuclear envelope morphology as well as colorectal cancer pathogenicity. We thus put forth RTN4 as a potential novel colorectal cancer therapeutic target and reveal a unique druggable hotspot within RTN4 that can be targeted by covalent ligands to impair colorectal cancer pathogenicity. Our results underscore the utility of coupling the screening of fragment-based covalent ligands with isoTOP-ABPP platforms for mining the proteome for novel druggable nodes that can be targeted for cancer therapy.